Hirani Rena, Karki Surendra, Irving David O
Research and Development, Australian Red Cross Lifeblood, Sydney, Australia; School of Natural Sciences, Macquarie University, Sydney, Australia.
Research and Development, Australian Red Cross Lifeblood, Sydney, Australia; School of Population Health, UNSW, Sydney, Australia.
Transfus Apher Sci. 2025 Jun;64(3):104129. doi: 10.1016/j.transci.2025.104129. Epub 2025 Apr 30.
Donor leucocyte survival, known as transfusion-associated microchimerism (TAM), following red blood cell (RBC) transfusion has been detected in adult trauma patients. Analysis of TAM prevalence in other cohorts has not been extensively analysed. The study aims to assess TAM prevalence in participants of a large ongoing Australian health and ageing study.
Participants from The Sax Institute's 45 and Up Study who had been identified as being transfused with at least one RBC unit using data linkage (n = 350) were approached between 8 February-8 December 2022 to provide blood samples for TAM analysis. Analysis of TAM was conducted using real-time PCR analysis with a panel of 12 biallelic insertion/deletion sequences.
Of the approached participants, 72 (55 males and 17 females) provided blood samples for analysis. The reason for RBC transfusion included trauma (n = 7), cancer treatment (n = 13), anaemia (n = 23) or surgery/other (n = 29). PCR results from 2 male and 9 female participants indicated potential TAM. Participants with potential TAM self-reported poor health (40.0 %) compared with those who did not have microchimerism detected (11.9 %). However, there were no significant differences in general practitioner visits, prescriptions filled or hospital admissions.
The prevalence of TAM in male participants in this small longitudinal cohort was lower compared to previous trauma studies. In female participants, 52.9 % indicated potential TAM, however naturally occurring sources of microchimerism remain possible. No direct long-term consequences related to potential TAM could be identified except poor self-reported health.
在成年创伤患者中已检测到红细胞（RBC）输注后供体白细胞存活现象，即输血相关微嵌合体（TAM）。其他队列中TAM患病率的分析尚未得到广泛开展。本研究旨在评估一项正在进行的大型澳大利亚健康与衰老研究参与者中TAM的患病率。
利用数据关联确定曾输注至少一个RBC单位的悉尼大学45岁及以上研究参与者（n = 350），在2022年2月8日至12月8日期间被邀请提供血样用于TAM分析。使用包含12个双等位基因插入/缺失序列的实时聚合酶链反应（PCR）分析TAM。
在被邀请的参与者中，72人（55名男性和17名女性）提供了血样用于分析。RBC输血的原因包括创伤（n = 7）、癌症治疗（n = 13）、贫血（n = 23）或手术/其他（n = 29）。2名男性和9名女性参与者的PCR结果表明存在潜在TAM。与未检测到微嵌合体的参与者相比，有潜在TAM的参与者自我报告健康状况较差（40.0%）。然而，在全科医生就诊次数、所开处方或住院情况方面没有显著差异。
与之前的创伤研究相比，这个小型纵向队列中男性参与者的TAM患病率较低。在女性参与者中，52.9%表明存在潜在TAM，然而微嵌合体的自然来源仍有可能。除了自我报告的健康状况较差外，未发现与潜在TAM相关的直接长期后果。
